25 XP   0   0   10

Genmab
Buy, Hold or Sell?

Let's analyse Genmab together

PenkeI guess you are interested in Genmab. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Genmab. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Genmab

I send you an email if I find something interesting about Genmab.

Quick analysis of Genmab (30 sec.)










What can you expect buying and holding a share of Genmab? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr322.14
Expected worth in 1 year
kr322.14
How sure are you?
45.5%

+ What do you gain per year?

Total Gains per Share
kr0.00
Return On Investment
0.0%

For what price can you sell your share?

Current Price per Share
kr1,966.50
Expected price per share
kr1,825 - kr2,167
How sure are you?
50%

1. Valuation of Genmab (5 min.)




Live pricePrice per Share (EOD)

kr1,966.50

2. Growth of Genmab (5 min.)




Is Genmab growing?

Current yearPrevious yearGrowGrow %
How rich?$3b$3b0.000.0%

How much money is Genmab making?

Current yearPrevious yearGrowGrow %
Making money$216.3m$142.1m$74.2m34.3%
Net Profit Margin0.0%9.6%--

How much money comes from the company's main activities?

3. Financial Health of Genmab (5 min.)




What can you expect buying and holding a share of Genmab? (5 min.)

Welcome investor! Genmab's management wants to use your money to grow the business. In return you get a share of Genmab.

What can you expect buying and holding a share of Genmab?

First you should know what it really means to hold a share of Genmab. And how you can make/lose money.

Speculation

The Price per Share of Genmab is kr1,967. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genmab.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genmab, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr322.14. Based on the TTM, the Book Value Change Per Share is kr0.00 per quarter. Based on the YOY, the Book Value Change Per Share is kr3.76 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genmab.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps2.950.1%3.270.2%2.150.1%2.170.1%2.170.1%
Usd Book Value Change Per Share0.000.0%0.000.0%0.540.0%4.200.2%4.200.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.0%0.540.0%4.200.2%4.200.2%
Usd Price Per Share372.67-382.26-363.65-359.77-359.77-
Price to Earnings Ratio31.61-43.71-54.80-60.30-60.30-
Price-to-Total Gains Ratio185.31-325.80-325.80-
Price to Book Ratio8.06-8.27-7.87-8.03-8.03-
Price-to-Total Gains Ratio185.31-325.80-325.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share282.19275
Number of shares3
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.004.20
Usd Total Gains Per Share0.004.20
Gains per Quarter (3 shares)0.0012.61
Gains per Year (3 shares)0.0050.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
100-1005040
200-10010190
300-100151140
400-100202190
500-100252240
600-100303290
700-100353340
800-100403390
900-100454440
1000-100504490

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%
Book Value Change Per Share0.00.03.00.0%5.00.06.045.5%5.00.06.045.5%5.00.06.045.5%5.00.06.045.5%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.011.00.0%0.00.011.00.0%0.00.011.00.0%
Total Gains per Share0.00.03.00.0%5.00.06.045.5%5.00.06.045.5%5.00.06.045.5%5.00.06.045.5%

Fundamentals of Genmab

About Genmab

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Fundamental data was last updated by Penke on 2024-04-15 16:23:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Genmab.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genmab earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Genmab to the  industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genmab:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY9.6%-9.6%
TTM-5Y16.6%-16.6%
5Y16.6%10Y16.6%0.0%
1.1.2. Return on Assets

Shows how efficient Genmab is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genmab to the  industry mean.
  • 5.7% Return on Assets means that Genmab generated kr0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genmab:

  • The MRQ is 5.7%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 6.3%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ5.7%TTM6.3%-0.6%
TTM6.3%YOY4.1%+2.2%
TTM6.3%5Y4.3%+2.0%
5Y4.3%10Y4.3%0.0%
1.1.3. Return on Equity

Shows how efficient Genmab is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genmab to the  industry mean.
  • 6.4% Return on Equity means Genmab generated kr0.06 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genmab:

  • The MRQ is 6.4%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.4%TTM7.1%-0.7%
TTM7.1%YOY4.7%+2.4%
TTM7.1%5Y4.8%+2.3%
5Y4.8%10Y4.8%0.0%

1.2. Operating Efficiency of Genmab.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genmab is operating .

  • Measures how much profit Genmab makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genmab to the  industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genmab:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY9.6%-9.6%
TTM-5Y7.1%-7.1%
5Y7.1%10Y7.1%0.0%
1.2.2. Operating Ratio

Measures how efficient Genmab is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Genmab:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000

1.3. Liquidity of Genmab.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genmab is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 14.93 means the company has kr14.93 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Genmab:

  • The MRQ is 14.927. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.370. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ14.927TTM13.370+1.556
TTM13.370YOY14.229-0.859
TTM13.3705Y13.737-0.367
5Y13.73710Y13.7370.000
1.3.2. Quick Ratio

Measures if Genmab is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genmab to the  industry mean.
  • A Quick Ratio of 2.42 means the company can pay off kr2.42 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genmab:

  • The MRQ is 2.415. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.464. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.415TTM2.464-0.049
TTM2.464YOY6.002-3.538
TTM2.4645Y10.020-7.556
5Y10.02010Y10.0200.000

1.4. Solvency of Genmab.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genmab assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genmab to industry mean.
  • A Debt to Asset Ratio of 0.11 means that Genmab assets are financed with 11.3% credit (debt) and the remaining percentage (100% - 11.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genmab:

  • The MRQ is 0.113. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.113. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.113TTM0.1130.000
TTM0.113YOY0.1130.000
TTM0.1135Y0.111+0.002
5Y0.11110Y0.1110.000
1.4.2. Debt to Equity Ratio

Measures if Genmab is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genmab to the  industry mean.
  • A Debt to Equity ratio of 12.7% means that company has kr0.13 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genmab:

  • The MRQ is 0.127. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.127. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.127TTM0.1270.000
TTM0.127YOY0.1270.000
TTM0.1275Y0.125+0.002
5Y0.12510Y0.1250.000

2. Market Valuation of Genmab

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Genmab generates.

  • Above 15 is considered overpriced but always compare Genmab to the  industry mean.
  • A PE ratio of 31.61 means the investor is paying kr31.61 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genmab:

  • The EOD is 23.937. Based on the earnings, the company is fair priced.
  • The MRQ is 31.612. Based on the earnings, the company is overpriced. -1
  • The TTM is 43.709. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD23.937MRQ31.612-7.675
MRQ31.612TTM43.709-12.097
TTM43.709YOY54.795-11.086
TTM43.7095Y60.302-16.593
5Y60.30210Y60.3020.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genmab:

  • The EOD is 95.820. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 126.542. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 106.040. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD95.820MRQ126.542-30.722
MRQ126.542TTM106.040+20.502
TTM106.040YOY122.552-16.512
TTM106.0405Y91.352+14.688
5Y91.35210Y91.3520.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genmab is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 8.06 means the investor is paying kr8.06 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Genmab:

  • The EOD is 6.104. Based on the equity, the company is overpriced. -1
  • The MRQ is 8.062. Based on the equity, the company is overpriced. -1
  • The TTM is 8.269. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.104MRQ8.062-1.957
MRQ8.062TTM8.269-0.207
TTM8.269YOY7.866+0.403
TTM8.2695Y8.030+0.239
5Y8.03010Y8.0300.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Genmab compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0%3.764-100%29.286-100%29.286-100%
Book Value Per Share--322.145322.1450%322.1450%312.354+3%312.354+3%
Current Ratio--14.92713.370+12%14.229+5%13.737+9%13.737+9%
Debt To Asset Ratio--0.1130.1130%0.1130%0.111+2%0.111+2%
Debt To Equity Ratio--0.1270.1270%0.1270%0.125+2%0.125+2%
Dividend Per Share----0%-0%-0%-0%
Eps--20.53822.818-10%14.991+37%15.135+36%15.135+36%
Free Cash Flow Per Share--5.13112.678-60%7.431-31%26.179-80%26.179-80%
Free Cash Flow To Equity Per Share--5.23710.135-48%6.531-20%24.674-79%24.674-79%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap--171591061600.000176006927066.667-3%167436734300.000+2%165597914354.545+4%165597914354.545+4%
Net Profit Margin----0%0.096-100%0.166-100%0.166-100%
Operating Margin----0%0.096-100%0.071-100%0.071-100%
Operating Ratio----0%-0%-0%-0%
Pb Ratio6.104-32%8.0628.269-3%7.866+2%8.030+0%8.030+0%
Pe Ratio23.937-32%31.61243.709-28%54.795-42%60.302-48%60.302-48%
Price Per Share1966.500-32%2597.0002663.833-3%2534.125+2%2507.136+4%2507.136+4%
Price To Free Cash Flow Ratio95.820-32%126.542106.040+19%122.552+3%91.352+39%91.352+39%
Quick Ratio--2.4152.464-2%6.002-60%10.020-76%10.020-76%
Return On Assets--0.0570.063-10%0.041+37%0.043+33%0.043+33%
Return On Equity--0.0640.071-10%0.047+37%0.048+33%0.048+33%
Total Gains Per Share----0%3.764-100%29.286-100%29.286-100%
Usd Book Value--3054397500.0003054397500.0000%3054397500.0000%2960535454.545+3%2960535454.545+3%
Usd Book Value Change Per Share----0%0.540-100%4.203-100%4.203-100%
Usd Book Value Per Share--46.22846.2280%46.2280%44.823+3%44.823+3%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--2.9473.274-10%2.151+37%2.172+36%2.172+36%
Usd Free Cash Flow--48646500.000120205166.667-60%70458500.000-31%248098454.545-80%248098454.545-80%
Usd Free Cash Flow Per Share--0.7361.819-60%1.066-31%3.757-80%3.757-80%
Usd Free Cash Flow To Equity Per Share--0.7511.454-48%0.937-20%3.541-79%3.541-79%
Usd Market Cap--24623317339.60025256994034.067-3%24027171372.050+2%23763300709.877+4%23763300709.877+4%
Usd Price Per Share282.193-32%372.670382.260-3%363.647+2%359.774+4%359.774+4%
Usd Profit--194729500.000216350166.667-10%142136750.000+37%143473909.091+36%143473909.091+36%
Usd Revenue----0%82871250.000-100%125640772.727-100%125640772.727-100%
Usd Total Gains Per Share----0%0.540-100%4.203-100%4.203-100%
 EOD+4 -1MRQTTM+4 -15YOY+10 -165Y+13 -1810Y+13 -18

3.2. Fundamental Score

Let's check the fundamental score of Genmab based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1523.937
Price to Book Ratio (EOD)Between0-16.104
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.415
Current Ratio (MRQ)Greater than114.927
Debt to Asset Ratio (MRQ)Less than10.113
Debt to Equity Ratio (MRQ)Less than10.127
Return on Equity (MRQ)Greater than0.150.064
Return on Assets (MRQ)Greater than0.050.057
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Genmab based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1,966.500
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in DKK. All numbers in thousands.

Summary
 As reported
Total Liabilities 0
Total Stockholder Equity+ 0
Total Assets = 0

Assets

Total Assets0
Total Current Assets29,749,000
Long-term Assets0
Total Current Assets
Net Receivables 4,814,000
Inventory 51,000
Total Current Assets  (as reported)29,749,000
Total Current Assets  (calculated)4,865,000
+/- 24,884,000
Long-term Assets
Property Plant Equipment 1,634,000
Long-term Assets  (as reported)0
Long-term Assets  (calculated)1,634,000
+/- 1,634,000

Liabilities & Shareholders' Equity

Total Current Liabilities1,993,000
Long-term Liabilities0
Total Stockholder Equity0
Total Current Liabilities
Other Current Liabilities 1,911,000
Total Current Liabilities  (as reported)1,993,000
Total Current Liabilities  (calculated)1,911,000
+/- 82,000
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock66,000
Other Stockholders Equity 112,000
Total Stockholder Equity (as reported)0
Total Stockholder Equity (calculated)178,000
+/- 178,000
Other
Net Tangible Assets 28,626,000
Net Working Capital 27,756,000



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2023-06-302022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
21,522,000
21,143,000
22,210,000
22,483,000
23,985,000
0
0
0
0
0
0
00000023,985,00022,483,00022,210,00021,143,00021,522,000
   > Total Current Assets 
19,504,000
18,791,000
19,937,000
20,304,000
21,954,000
22,736,000
23,175,000
25,491,000
28,739,000
28,377,000
29,749,000
29,749,00028,377,00028,739,00025,491,00023,175,00022,736,00021,954,00020,304,00019,937,00018,791,00019,504,000
       Cash And Cash Equivalents 
8,892,000
7,260,000
7,892,000
9,477,000
8,729,000
0
0
0
0
0
0
0000008,729,0009,477,0007,892,0007,260,0008,892,000
       Short-term Investments 
8,577,000
8,819,000
10,191,000
8,398,000
10,014,000
0
0
0
0
0
0
00000010,014,0008,398,00010,191,0008,819,0008,577,000
       Net Receivables 
2,035,000
2,463,000
1,854,000
2,429,000
3,211,000
3,398,000
3,187,000
3,876,000
4,951,000
6,053,000
4,814,000
4,814,0006,053,0004,951,0003,876,0003,187,0003,398,0003,211,0002,429,0001,854,0002,463,0002,035,000
   > Long-term Assets 00000000000
       Property Plant Equipment 
730,000
736,000
842,000
919,000
957,000
975,000
975,000
1,238,000
1,289,000
1,322,000
1,634,000
1,634,0001,322,0001,289,0001,238,000975,000975,000957,000919,000842,000736,000730,000
       Intangible Assets 
385,000
338,000
317,000
297,000
275,000
0
0
0
0
0
0
000000275,000297,000317,000338,000385,000
> Total Liabilities 
3,045,000
2,022,000
2,115,000
2,231,000
2,700,000
0
0
0
0
0
0
0000002,700,0002,231,0002,115,0002,022,0003,045,000
   > Total Current Liabilities 
2,258,000
1,253,000
1,293,000
1,351,000
1,830,000
1,568,000
1,339,000
1,944,000
2,988,000
1,823,000
1,993,000
1,993,0001,823,0002,988,0001,944,0001,339,0001,568,0001,830,0001,351,0001,293,0001,253,0002,258,000
       Accounts payable 
0
0
0
0
0
350,000
0
0
0
0
0
00000350,00000000
       Other Current Liabilities 
0
0
0
1,292,000
1,767,000
860,000
1,279,000
1,864,000
2,909,000
1,749,000
1,911,000
1,911,0001,749,0002,909,0001,864,0001,279,000860,0001,767,0001,292,000000
   > Long-term Liabilities 00000000000
       Other Liabilities 
0
0
0
496,000
496,000
500,000
500,000
496,000
491,000
491,000
509,000
509,000491,000491,000496,000500,000500,000496,000496,000000
> Total Stockholder Equity
18,477,000
19,121,000
20,095,000
20,252,000
21,285,000
0
0
0
0
0
0
00000021,285,00020,252,00020,095,00019,121,00018,477,000
   Common Stock
65,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,00066,00066,00066,00066,00066,00066,00066,00066,00066,00065,000
   Retained Earnings 
6,537,000
7,161,000
8,020,000
8,164,000
9,139,000
10,020,000
10,512,000
12,243,000
14,299,000
14,968,000
16,165,000
16,165,00014,968,00014,299,00012,243,00010,512,00010,020,0009,139,0008,164,0008,020,0007,161,0006,537,000
   Capital Surplus 
11,875,000
11,894,000
11,914,000
11,940,000
11,996,000
0
0
0
0
0
0
00000011,996,00011,940,00011,914,00011,894,00011,875,000
   Treasury Stock00000000000
   Other Stockholders Equity 
0
0
95,000
82,000
84,000
81,000
97,000
110,000
151,000
98,000
112,000
112,00098,000151,000110,00097,00081,00084,00082,00095,00000



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-0
Operating Income00
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense00
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income0
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)00
EBIT - interestExpense = 6,395,000
1,513,000
0
Interest Expense0
Earnings Before Interest and Taxes (EBIT)6,395,0000
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax0
Tax Provision-0
Net Income From Continuing Ops00
Net Income0
Net Income Applicable To Common Shares5,522,000
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net00
 

Technical Analysis of Genmab
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genmab. The general trend of Genmab is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genmab's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genmab.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2,123 < 2,136 < 2,167.

The bearish price targets are: 1,893 > 1,825.

Tweet this
Genmab Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genmab. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genmab Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genmab.

Genmab Daily Moving Average Convergence/Divergence (MACD) ChartGenmab Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genmab. The current adx is .

Genmab Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genmab.

Genmab Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genmab.

Genmab Daily Relative Strength Index (RSI) ChartGenmab Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genmab.

Genmab Daily Stochastic Oscillator ChartGenmab Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genmab.

Genmab Daily Commodity Channel Index (CCI) ChartGenmab Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genmab.

Genmab Daily Chande Momentum Oscillator (CMO) ChartGenmab Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genmab.

Genmab Daily Williams %R ChartGenmab Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Genmab.

Genmab Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genmab.

Genmab Daily Average True Range (ATR) ChartGenmab Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genmab.

Genmab Daily On-Balance Volume (OBV) ChartGenmab Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genmab.

Genmab Daily Money Flow Index (MFI) ChartGenmab Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genmab.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Genmab Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genmab based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1,966.500
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Genmab with someone you think should read this too:
  • Are you bullish or bearish on Genmab? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genmab? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genmab

I send you an email if I find something interesting about Genmab.


Comments

How you think about this?

Leave a comment

Stay informed about Genmab.

Receive notifications about Genmab in your mailbox!